 | • レポートコード：MRC2203A224 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の医療における低温プラズマ市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、用途別（創傷治癒、血液凝固、歯科、がん治療、その他）分析、レジーム別（低圧低温プラズマ、大気低温プラズマ）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の医療における低温プラズマ市場規模：用途別（創傷治癒、血液凝固、歯科、がん治療、その他） ・世界の医療における低温プラズマ市場規模：レジーム別（低圧低温プラズマ、大気低温プラズマ） ・世界の医療における低温プラズマ市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（ADTEC Plasma Technology Co.Ltd、Wacker Chemie AG、Europlasma NV、…） ・市場機会・将来傾向 |
The cold plasma in healthcare market is expected to register a CAGR of 12.5% during the forecast period, 2021-2026. The market is expected to show good growth due to the benefits associated with cold plasma techniques and the increasing use of cold plasma in wound healing.
With the rising number of COVID-19 patients, plasma therapy has shown positive results for coronavirus treatment. Cold plasma treatment is also being touted as an effective remedy against the ongoing COVID-19 pandemic. The demand for plasma therapy is increasing due to its potential use in coronavirus treatment. The United States, China, Turkey, Spain, and the United Kingdom are few countries that are also looking at plasma therapy to more easily address the worldwide COVID-19 crisis. Even in India, it was found that in Delhi, a hospital has successfully cured a COVID-19 patient using plasma therapy. The patients were found with increased respiratory rate and oxygen saturation level.
The field of cold plasma in medicine is thus growing quickly as cold plasma has the ability to kill bacteria and prevent infections, and it has been proven to be successful in treating burns.
According to the Canadian Cancer Society, an estimated 27,400 women were diagnosed with breast cancer in the country in 2020. This represents 25% of all new cancer cases in women by 2020, with 5,100 women dying from breast cancer. Gas plasmas or ionized gases have many developing applications in cancer treatment, and hence, as the cancer cases increase, the market is likely to grow shortly.
Also, cold plasma is effectively combined with chemotherapy in cancer treatment and promotes wound sterilization, blood coagulation, and cell proliferation in wound healing. Its use allows for effective medical treatment of cancer and various skin injuries and diseases.
It has also been found that recently, cold plasma was also used in Germany in limited preliminary trials as palliative therapy for head and neck cancer patients. Therefore, the rising applications of cold plasma in wound healing, cancer treatment, and infective diseases are augmenting the growth of the market studied.
Key Market Trends
The Wound Healing Segment is Expected to Hold a Significant Market Share
The wound healing segment is expected to hold a high market share as cold plasma has the ability to kill bacteria, including drug-resistant bacteria, to prevent further infection rate and thus helps in treating chronic wounds. It is also found to boost the wound healing process and eliminates further complications.
With the rising COVID-19, the demand for cold plasma is found to increase. The basis for this development is provided by Plasma Care that is a CE-mark approved medical device that generates cold atmospheric plasma that was found to be developed for the mobile treatment of acute and chronic wounds.
According to the World Health Organization 2020, there are more than 1.35 million people that die every year as a result of road traffic crashes and accidents. Road traffic injuries are the leading cause of death among people aged between 15 and 29 years. Every year, the lives of more than 1.35 million people are cut short as a result of road traffic crashes. Therefore, since there are a large number of trauma and wound management cases observed yearly, the adoption rate of cold plasma is expected to be high for wound healing across hospitals and healthcare facilities.
Moreover, as per the Germany Federal Statistical Office 2020 report, currently, there are about 83 million people in Germany, of which 16.2 million people are above 67 years of age, and it is projected to reach 21.4 million by 2040. With the increase in the geriatric population, there is an increasing diabetic population, which results in chronic wounds such as foot ulcers and thus boosts the overall market.
Although many other treatment procedures are present for wound healing, cold plasma treatment is anticipated to be one of the effective ways that drive the overall segment further.
North America is Expected to Hold a Significant Share in the Market and is Expected to do the Same in the Forecast Period
North America dominates the cold plasma market owing to the presence of key industry participants and the availability of various FDA-approved products. There has been a rising adoption of technologically advanced products that also fuel the market growth.
With the rising COVID-19, the demand for plasma therapy is found increasing. Based on the recent 2020 study, UCLA engineers and scientists have demonstrated that treatments with near-room-temperature, cold atmospheric plasma can kill the coronavirus present on a variety of surfaces. The study published in the journal Physics of Fluids marks the first time cold plasma has been shown to effectively and quickly disinfect surfaces contaminated with the SARS-CoV-2 virus that causes COVID-19. The potential of cold atmospheric plasma is a safe and effective way to fight the transmission of the virus by killing it on a wide range of surfaces.
According to Breast Cancer.org statistics, breast cancer most commonly occurs among women in North America. As of January 2020, around 3.5 million women have a history of breast cancer in the United States. Also, breast cancer is the most diagnosed cancer among women in the United States. It is also estimated that around 30% of newly diagnosed cancers in women are breast cancers. In addition to the source mentioned above, an estimated 276,480 cases of invasive breast cancer and approximately 48,530 new carcinoma cases in situ (CIS) are expected to be diagnosed in 2020. Moreover, the average risk of a woman in the United States developing breast cancer in her life is about 13%. Therefore, with the increasing prevalence of cancer and chronic wounds, the market is expected to grow.
In addition, the Asia-Pacific market is expected to register high growth primarily due to the growing demand for cold plasma technology and a majority of global companies focusing on developing and expanding their R&D capabilities and distribution networks in this region. Rise in disposable income levels and the growing target population base are also likely to contribute to the overall market growth.
Competitive Landscape
The cold plasma in the healthcare market is consolidated competitive. Some of the key companies in the cold plasma market are U.S. Medical Innovations LLC, Bovie Medical Corporation, Neoplas Tools GmbH, Europlasma NV, and P2i Limited. The key players involved in market expansion analyze competitive developments (such as partnerships, agreements, collaborations, alliances, mergers and acquisitions, new product developments, geographical expansions, and R&D activities) and strategically and comprehensively analyze their core competencies in the cold plasma market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Environment Friendliness and Other Benefits of Cold Plasma Techniques
4.2.2 Increasing Use of Cold Plasma in Wound Healing
4.3 Market Restraints
4.3.1 Lack of Awareness about Cold Plasma Technology in the Healthcare Industry
4.3.2 Stringent Regulatory Policies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Wound Healing
5.1.2 Blood Coagulation
5.1.3 Dentistry
5.1.4 Cancer Treatment
5.1.5 Other Medical Applications
5.2 By Regime
5.2.1 Low-pressure Cold Plasma
5.2.2 Atmospheric Cold Plasma
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 ADTEC Plasma Technology Co. Ltd
6.1.2 Wacker Chemie AG
6.1.3 Europlasma NV
6.1.4 Neoplas med GmbH
6.1.5 Nordson Corporation
6.1.6 P2I Limited
6.1.7 Plasmatreat GmbH
6.1.8 Tantec AS
6.1.9 U.S. Medical Innovations
6.1.10 Enercon Industries Corporation
6.1.11 terraplasma medical GmbH
6.1.12 VETAPHONE AS
6.1.13 TOMI Environmental Solutions Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS